13 February 2018 | News
This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall
Lonza announced the latest addition to its cell-culture product portfolio with the Quasi Vivo® System.
The Quasi Vivo® Device consists of an advanced, interconnected fluidics system to create more physiologically relevant cell-culture conditions, helping researchers improve the predictive value of their studies.
This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall (a biotechnology company based in Rotherham, UK).
Kirkstall developed the Quasi Vivo® System, which consists of interconnected cell-culture chambers and a peristaltic pump to create a continuous flow of media over cells.
As a result, cultures are exposed to more physiologically relevant conditions, increasing the predictive value of in vitro experiments.
The Quasi Vivo® System is available with three different culture chambers (QV500, QV600, and QV900) to support a wide range of applications, including submerged cell culture, co-culture and modeling of air-liquid and liquid-liquid interfaces.
Not only is the Quasi Vivo® System easy to set up, it also enables close monitoring of variables during an experiment.
Furthermore, the large scale and user configurability of the Quasi Vivo® System allows assays to be performed that are not possible using microfluidic systems.